Impact of nutrition on phenotype in CFTR-deficient mice

Pediatric Research

Volumn 62, Issue 5, 2007, Pages 528-532

  Cottart, Charles Henry ^a   Bonvin, Elise ^a   Rey, Colette ^a   Wendum, Dominique ^c,d   Bernaudin, Jean François ^b,c   Dumont, Sylvie ^c   Lasnier, Elisabeth ^d   Debray, Dominique ^a   ClIment, Annick ^a   Housset, Chantal ^a   Bonora, Monique ^a,d  

^a INSERM   (France)

^b EA3499   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; FATTY LIVER; HEPATOMEGALY; INTESTINE OBSTRUCTION; MALE; MORTALITY; MOUSE; NONHUMAN; NUTRITION; PHENOTYPE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; SURVIVAL RATE; WEANING; ANIMAL; ANIMAL FOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GENETICS; GROWTH DISORDER; LIVER; LUNG; LUNG VENTILATION; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

LAXATIVE; MACROGOL 3350; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEPTAMEN; UNCLASSIFIED DRUG;

ANIMAL NUTRITION PHYSIOLOGY; ANIMALS; BODY WEIGHT; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; FATTY LIVER; GROWTH DISORDERS; HEPATOMEGALY; INTESTINAL OBSTRUCTION; LAXATIVES; LIVER; LUNG; MALE; MICE; MICE, INBRED CFTR; OLIGOPEPTIDES; PHENOTYPE; POLYETHYLENE GLYCOLS; PULMONARY VENTILATION; TIME FACTORS;

EID: 38849138757     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318155a61d     Document Type: Article

References (30)

1. Zielenski J 2000 Genotype and phenotype in cystic fibrosis. Respiration 67:117-133
2. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, Sereni LP 1994 Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 124:393-399
3. Pencharz PB, Durie PR 2000 Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr 19:387-394
4. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F 2004 Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 41:920-925
5. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ 2003 Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 142:624-630
6. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH 1992 An animal model for cystic fibrosis made by gene targeting. Science 257:1083-1088
7. Clarke LL, Gawenis LR, Franklin CL, Harline MC 1996 Increased survival of CFTR knockout mice with an oral osmotic laxative. Lab Anim Sci 46:612-618
8. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG 1999 A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A 96:13995-14000
9. Kent G, Oliver M, Foskett JK, Frndova H, Durie P, Forstner J, Forstner GG, Riordan JR, Percy D, Buchwald M 1996 Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res 40:233-241
10. Bartlett D, Jr. Tenney SM 1970 Control of breathing in experimental anemia. Respir Physiol 10:384-395
11. Eckman EA, Cotton CU, Kube DM, Davis PB 1995 Dietary changes improve survival of CFTR S489X homozygous mutant mouse. Am J Physiol 269:L625-L630
12. Rosenberg LA, Schluchter MD, Parlow AF, Drumm ML 2006 Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res 59:191-195
13. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, Shen G, Walker S, Farrell PM 1998 Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. J Pediatr 132:478-485
14. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA 2000 Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 137:374-380
15. Kent G, Iles R, Bear CE, Huan LJ, Griesenbach U, McKerlie C, Frndova H, Ackerley C, Gosselin D, Radzioch D, O'Brodovich H, Tsui LC, Buchwald M, Tanswell AK 1997 Lung disease in mice with cystic fibrosis. J Clin Invest 100:3060-3069
16. Haston CK, McKerlie C, Newbigging S, Corey M, Rozmahel R, Tsui LC 2002 Detection of modifier loci influencing the lung phenotype of cystic fibrosis knockout mice. Mamm Genome 13:605-613
17. Bonora M, Bernaudin JF, Guernier C, Brahimi-Horn MC 2004 Ventilatory responses to hypercapnia and hypoxia in conscious cystic fibrosis knockout mice Cftr-/-. Pediatr Res 55:738-746
18. Cohen JC, Lundblad LK, Bates JH, Levitzky M, Larson JE 2004 The "Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genet 5:21-26
19. Mortola JP, Matsuoka T, Saiki C, Naso L 1994 Metabolism and ventilation in hypoxic rats: effect of body mass. Respir Physiol 97:225-234
20. Colombo C, Battezzati PM 2004 Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol 41:1041-1044
21. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG 1993 Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 105:1857-1864
22. Scoazec JY, Bringuier AF, Medina JF, Martinez-Anso E, Veissiere D, Feldmann G, Housset C 1997 The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications. J Hepatol 26:543-553
23. Dray-Charier N, Paul A, Scoazec JY, Veissiere D, Mergey M, Capeau J, Soubrane O, Housset C 1999 Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Hepatology 29:1624-1634
24. Kinnman N, Lindblad A, Housset C, Buentke E, Scheynius A, Strandvik B, Hultcrantz R 2000 Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology 32:334-340
25. Lindblad A, Glaumann H, Strandvik B 1999 Natural history of liver disease in cystic fibrosis. Hepatology 30:1151-1158
26. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Christensen H, Luk C, Yantiss RK, Nasser IA, Zaman M, Freedman SD, Durie PR 2007 Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 292:G839-G848
27. Durie PR, Kent G, Phillips MJ, Ackerley CA 2004 Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 164:1481-1493
28. Ratziu V, Poynard T 2006 Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44:802-805
29. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ 2001 Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17-26
30. Peretti N, Marcil V, Drouin E, Levy E 2005 Mechanisms of lipid malabsorption in cystic fibrosis: the impact of essential fatty acids deficiency. Nutr Metab (Lond) 2:11